Loading...
XSHE
002755
Market cap2.33bUSD
Jun 16, Last price  
17.94CNY
1D
-4.32%
1Q
5.78%
Jan 2017
-20.58%
IPO
170.71%
Name

Beijing Aosaikang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
11.54
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.28%
Rev. gr., 5y
-18.16%
Revenues
1.44b
-22.92%
529,171,408494,258,426500,424,755470,869,196278,157,189178,357,925365,933,9303,931,881,7264,518,631,6923,782,688,9123,106,666,5691,872,572,1891,443,459,608
Net income
-149m
49,135,19159,954,11255,521,02537,504,22718,864,5364,604,64610,966,920670,073,623780,959,203721,625,102379,907,7870-148,529,759
CFO
-27m
0106,470,20200016,729,5320497,158,803534,615,973580,383,967567,707,6500-26,568,451
Dividend
Jun 20, 20220.1 CNY/sh

Profile

Beijing Aosaikang Pharmaceutical Co., Ltd. researches, develops, manufactures, markets, and sells pharmaceuticals, fine chemicals, and health-care products in China. It offers proton pump inhibitor injections and oncology medicines, as well as APIs. The company provides its products in digestive, oncology, antibiotic, and other areas. Beijing Aosaikang Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.
URL
http://www.ask-pharm.com/
IPO date
May 15, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,443,460
-22.92%
1,872,572
-39.72%
Cost of revenue
1,622,923
2,072,328
Unusual Expense (Income)
NOPBT
(179,464)
(199,756)
NOPBT Margin
Operating Taxes
6,550
3,701
Tax Rate
NOPAT
(186,014)
(203,457)
Net income
(148,530)
 
Dividends
(92,816)
Dividend yield
1.26%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
114,019
48,487
Long-term debt
13,508
17,837
Deferred revenue
64,720
55,808
Other long-term liabilities
2
1
Net debt
(1,037,731)
(1,545,467)
Cash flow
Cash from operating activities
(26,568)
CAPEX
(129,319)
Cash from investing activities
11,563
Cash from financing activities
291,174
75,912
FCF
12,179
56,695
Balance
Cash
1,760,873
1,611,791
Long term investments
(595,616)
Excess cash
1,093,085
1,518,162
Stockholders' equity
2,625,515
2,965,719
Invested Capital
2,103,091
1,593,627
ROIC
ROCE
EV
Common stock shares outstanding
928,311
928,160
Price
10.82
36.27%
7.94
-36.98%
Market cap
10,044,325
36.29%
7,369,593
-36.98%
EV
9,117,291
5,874,496
EBITDA
(94,763)
(107,564)
EV/EBITDA
Interest
3,080
2,764
Interest/NOPBT